Labgenomics Co

Labgenomics Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is 47.44 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 54.61 % — a change of -13.14% (lower).

Cash Conversion

47.44 %

YoY

-13.14%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Labgenomics Co is 2025 47.44 % . Cash Conversion Rate (OCF/Net Income) of Labgenomics Co was 2024 54.61 % . It decreases by -13.14% lower compared to the previous year.

The Labgenomics Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-15.30 KRW
Jan 1, 2019
331.26 KRW
Jan 1, 2020
108.43 KRW
Jan 1, 2021
77.95 KRW
Jan 1, 2022
144.36 KRW
Jan 1, 2023
-51.82 KRW
Jan 1, 2024
54.61 KRW
Jan 1, 2025
47.44 KRW
The Labgenomics Co Cash Conversion history
YEARCash ConversionYoY
47.44 %-13.14%
54.61 %-205.39%
-51.82 %-135.89%
144.36 %+85.21%
77.95 %-28.11%
108.43 %-67.27%
331.26 %-2,264.43%
-15.30 %-149.76%
30.75 %-91.25%
351.38 %+140.47%
146.12 %+12.39%
130.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Cash Conversion Rate (OCF/Net Income) of Labgenomics Co is 47.44 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Labgenomics Co changed from 54.61 % to 47.44 %, representing a -13.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labgenomics Co

All Key Metrics — Labgenomics Co